Genetic Engineering Drug Market Trends 2021 | Segmentation, Outlook, Industry Report to 2027
The global genetic engineering drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Genetic engineering drugs include hormones, enzymes, growth and coagulation factors, antibodies as well as vaccines and are generated by using recombinant DNA technology. Additionally, they are categorized by high and specific activity in the presence of optimal safety. The major factor driving the demand for the genetic engineering drug is the new drug launches and strategic initiatives from the key players in the market across the globe.
For instance, in December 2021,
GlaxoSmithKline plc announced a five-year collaboration with Lyell
Immunopharma. The collaboration was aimed to develop new technologies to
improve cell therapies for cancer patients and will apply Lyell’s technologies
to further strengthen GSK’s cell therapy pipeline which includes GSK3377794.
GSK3377794 uses genetically engineered autologous T cells and is currently in
Phase 2. Additionally, in January 2022, Pfizer Inc. announced an exclusive
four-year research collaboration with Beam Therapeutics Inc. The collaboration
is focused on in vivo base editing programs for three targets for rare genetic
diseases of the liver, muscle and central nervous system
To Request a Sample of our Report on Genetic Engineering
Drug Market: https://www.omrglobal.com/request-sample/genetic-engineering-drug-market
Some major players in the market include Pfizer Inc.,
GlaxoSmithKline plc, and Eli Lilly and Co., among others. The market players
are contributing significantly to the growth of the market by the adoption of
various strategies including mergers & acquisitions, geographical
expansion, partnerships and collaborations, and new product launches, to stay
competitive in the market. For instance, in February 2022, Eli Lilly and
Company announced the launch of the Lilly Institute for Genetic Medicine.
Additionally, the company announced an investment of approximately $700 million
to establish a state-of-the-art facility at a new site in the Boston Seaport.
Market Coverage
•
The market number available for – 2020-2027
•
Base year- 2020
•
Forecast period- 2021-2027
Segment Covered-
•
By Product
•
By Application
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape-
Pfizer Inc., GlaxoSmithKline plc, and Eli Lilly and Co., among others.
(Get 15% Discount on Buying this Report)
A
full Report of Genetic Engineering Drug Market is Available @ https://www.omrglobal.com/industry-reports/genetic-engineering-drug-market
Global Genetic Engineering Drug Market Report by Segment
By Product
• Monoclonal
Antibody
• Recombinant
Human Erythropoietin
• Recombinant
Human Interferon
• Recombinant
Human Growth Hormone
• Recombinant
Human Insulin
By Application
• Less Than
30 Years Old
• 30
Years-60 Years Old
• Above 60
Years
Global Genetic Engineering Drug Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment